ATE450511T1 - Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonists - Google Patents
Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonistsInfo
- Publication number
- ATE450511T1 ATE450511T1 AT04751604T AT04751604T ATE450511T1 AT E450511 T1 ATE450511 T1 AT E450511T1 AT 04751604 T AT04751604 T AT 04751604T AT 04751604 T AT04751604 T AT 04751604T AT E450511 T1 ATE450511 T1 AT E450511T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- receptor agonist
- adrenergene
- arylaniline
- sub
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000012453 solvate Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108060003345 Adrenergic Receptor Proteins 0.000 abstract 1
- 102000017910 Adrenergic receptor Human genes 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46881003P | 2003-05-08 | 2003-05-08 | |
| PCT/US2004/014302 WO2004101525A1 (en) | 2003-05-08 | 2004-05-07 | Crystalline form of aryl aniline beta-2 adrenergic receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450511T1 true ATE450511T1 (de) | 2009-12-15 |
Family
ID=33452233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04751604T ATE450511T1 (de) | 2003-05-08 | 2004-05-07 | Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonists |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7060712B2 (de) |
| EP (1) | EP1622875B1 (de) |
| JP (1) | JP2006528242A (de) |
| AT (1) | ATE450511T1 (de) |
| DE (1) | DE602004024383D1 (de) |
| WO (1) | WO2004101525A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| AR040962A1 (es) * | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| EP1786762A2 (de) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidin-substituierte arylanilinverbindungen |
| GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| EA200701260A1 (ru) * | 2005-01-11 | 2008-02-28 | Глаксо Груп Лимитед | Циннаматные соли бета-2 адренергического агониста |
| GB0512246D0 (en) * | 2005-06-15 | 2005-07-27 | Glaxo Group Ltd | Novel pharmaceutical |
| TW200811104A (en) * | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| TW200840578A (en) * | 2006-12-15 | 2008-10-16 | Procter & Gamble | Compositions of azimilide dihydrochloride |
| US20120178762A1 (en) | 2006-12-15 | 2012-07-12 | Warner Chilcott Company, Llc | Compositions of azimilide dihydrochloride |
| ES2320961B1 (es) * | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
| KR20180085068A (ko) | 2011-06-10 | 2018-07-25 | 키에시 파르마슈티시 엣스. 피. 에이. | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| PL3517541T3 (pl) | 2012-05-08 | 2020-12-28 | Nicox Ophthalmics, Inc. | Postać polimorficzna propionianu flutykazonu |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894219A (en) * | 1988-03-29 | 1990-01-16 | University Of Florida | Beta-agonist carbostyril derivatives, assay method and pharmacological composition |
| GB9713819D0 (en) | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| ES2438985T3 (es) | 2001-09-14 | 2014-01-21 | Glaxo Group Limited | Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) * | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| ATE381535T1 (de) | 2002-04-25 | 2008-01-15 | Glaxo Group Ltd | Phenethanolaminderivate |
-
2004
- 2004-05-07 DE DE602004024383T patent/DE602004024383D1/de not_active Expired - Fee Related
- 2004-05-07 JP JP2006532854A patent/JP2006528242A/ja not_active Withdrawn
- 2004-05-07 WO PCT/US2004/014302 patent/WO2004101525A1/en not_active Ceased
- 2004-05-07 AT AT04751604T patent/ATE450511T1/de not_active IP Right Cessation
- 2004-05-07 US US10/841,761 patent/US7060712B2/en not_active Expired - Lifetime
- 2004-05-07 EP EP04751604A patent/EP1622875B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1622875B1 (de) | 2009-12-02 |
| DE602004024383D1 (de) | 2010-01-14 |
| JP2006528242A (ja) | 2006-12-14 |
| US7060712B2 (en) | 2006-06-13 |
| WO2004101525A1 (en) | 2004-11-25 |
| US20040224982A1 (en) | 2004-11-11 |
| EP1622875A1 (de) | 2006-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200510277A (en) | Crystalline form of β2-adrenergic receptor agonist | |
| DE602004024383D1 (de) | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists | |
| MXPA04004505A (es) | Agonistas del receptor adrenergico beta2 de aril anilina. | |
| MY139296A (en) | CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONIST | |
| ATE447408T1 (de) | Kombinationen aus einem arylanilin-beta-2- adrenozeptor-agonisten und einem corticosteroid | |
| BRPI0506823A (pt) | derivados de aril anilina como agonistas de receptor beta2 adrenérgico | |
| MA29088B1 (fr) | Composes d'indazole-carboxamide. | |
| WO2005121065A3 (en) | DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS | |
| WO2005030678A3 (en) | AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS | |
| MY155036A (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| BRPI0507791A (pt) | compostos de indazol-carboxamida como agonistas do receptor 5-ht4 | |
| NO20074567L (no) | Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse | |
| ATE390922T1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| ATE441646T1 (de) | 5-ht4-rezeptoragonistenverbindungen | |
| WO2006052889A3 (en) | Quinolinone-carboxamide compounds | |
| NO20061981L (no) | Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist | |
| DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| TW200716607A (en) | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | |
| WO2003072572A8 (en) | Beta3-adrenergic receptor agonists | |
| TW200640921A (en) | Crystalline form of an indazole-carboxamide compound | |
| BRPI0608392A2 (pt) | compostos de quinolinona como agonistas do receptor 5-ht4 | |
| MY143574A (en) | Carbamate compounds as 5-ht4 receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |